Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Randomized, Double-blind, Parallel, Placebo-controlled Study Assessing The Efficacy and Safety of Sarilumab Added To DMARD Therapy In Patients With Rheumatoid Arthritis Who Are Inadequate Responders To Or Intolerant Of TNF-alpha Antagonists

Next Previous
Trial Profile

A Randomized, Double-blind, Parallel, Placebo-controlled Study Assessing The Efficacy and Safety of Sarilumab Added To DMARD Therapy In Patients With Rheumatoid Arthritis Who Are Inadequate Responders To Or Intolerant Of TNF-alpha Antagonists

Status: Completed
Phase of Trial: Phase III

Latest Information Update: 25 Nov 2022

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Sarilumab (Primary) ; Hydroxychloroquine; Leflunomide; Methotrexate; Sulfasalazine
  • Indications Rheumatoid arthritis
  • Focus Registrational; Therapeutic Use
  • Acronyms RA-TARGET; SARIL-RA-TARGET; TARGET
  • Sponsors Sanofi

    • Most Recent Events

    • 22 Nov 2022 Results of pooled analysis from (NCT01061736, NCT02332590, NCT01709578, NCT01146652) assessing disproportionate articular pain prevalence and effects of sarilumab published in the Rheumatology
    • 14 Nov 2022 Results (n=112) of secondary analysis of the TARGET randomized active comparator trial, presented at the ACR Convergence 2022
    • 25 Aug 2022 Results of pooled post hoc analyses assessing clinical outcomes from three phase III trials: TARGET, MOBILITY, and MONARCH published in the Arthritis Research and Therapy
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Legal
Back to top